Biotech Showcase™ 2016: Interview: Renova develops gene therapies for CHF and type 2 diabetes

Renova Therapeutics co-founder and CEO Dr. Jack Reich tells Informa Pharma Insights director of global content Mike Ward how his company is developing once-in-a-lifetime gene therapies to treat both congestive heart failure and type 2 diabetes. The lead program, designed to revive AC6 levels to restore heart function to normal levels, has completed a Phase II trial in collaboration with NIH in a public-private partnership. The company is now planning to run a Phase III trial in the European Union and US by the end of 2016. In addition, Reich explains how second generation gene therapies that can be administered through intravenous injection, targeting CHF and type II diabetes, are expected to be put into clinical trials later this year.